InterOcean Capital LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 52.1% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,034 shares of the medical research company’s stock after selling 1,123 shares during the quarter. InterOcean Capital LLC’s holdings in Thermo Fisher Scientific were worth $293,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $1,411,603,000. Fisher Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 55,392.1% in the 1st quarter. Fisher Asset Management LLC now owns 944,476 shares of the medical research company’s stock valued at $267,853,000 after purchasing an additional 942,774 shares during the last quarter. Farallon Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $277,166,000. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Thermo Fisher Scientific by 30.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,217,273 shares of the medical research company’s stock worth $628,819,000 after purchasing an additional 519,525 shares during the last quarter. Finally, Girard Partners LTD. lifted its holdings in shares of Thermo Fisher Scientific by 2,841.5% during the first quarter. Girard Partners LTD. now owns 528,475 shares of the medical research company’s stock worth $5,506,000 after purchasing an additional 510,509 shares during the period. 88.68% of the stock is currently owned by institutional investors.
Shares of NYSE:TMO traded up $4.51 during trading on Friday, hitting $340.26. 1,097,619 shares of the stock were exchanged, compared to its average volume of 1,572,086. The company has a market cap of $132.60 billion, a PE ratio of 37.31, a P/E/G ratio of 2.25 and a beta of 1.04. The company has a current ratio of 2.32, a quick ratio of 1.69 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average price of $324.75 and a two-hundred day moving average price of $317.43. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $351.86.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 22nd. The medical research company reported $2.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.79 by $0.15. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6.18 billion. Thermo Fisher Scientific had a return on equity of 17.25% and a net margin of 14.31%. Thermo Fisher Scientific’s revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.81 earnings per share. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 11.92 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.26%. The ex-dividend date of this dividend is Friday, June 12th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.13%.
In related news, COO Mark Stevenson sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of $328.03, for a total value of $8,200,750.00. Following the sale, the chief operating officer now owns 73,538 shares of the company’s stock, valued at approximately $24,122,670.14. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 30,000 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $333.02, for a total value of $9,990,600.00. Following the sale, the chief executive officer now owns 304,946 shares in the company, valued at approximately $101,553,116.92. The disclosure for this sale can be found here. 0.45% of the stock is owned by insiders.
Several equities analysts have issued reports on TMO shares. Needham & Company LLC boosted their price objective on shares of Thermo Fisher Scientific from $341.00 to $383.00 in a research note on Thursday, April 23rd. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $340.00 to $341.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $345.00 to $315.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Wells Fargo & Co lifted their price objective on Thermo Fisher Scientific from $300.00 to $340.00 and gave the company an “equal weight” rating in a report on Tuesday, April 21st. Finally, Citigroup increased their target price on Thermo Fisher Scientific from $365.00 to $390.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $347.21.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: What does an inverted yield curve signify?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.